A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 2, 2006, Pages 349-358

  Alou, Luis ^a   Giménez, María José ^a   Sevillano, David ^a   Aguilar, Lorenzo ^a   Cafini, Fabio ^a   Echeverría, Olatz ^a   Pérez Trallero, Emilio ^b   Prieto, José ^a  

^a SCHOOL OF MEDICINE   (Spain)

^b HOSPITAL DONOSTIA   (Spain)

Author keywords

Azithromycin; Levofloxacin; Moxifloxacin; Pharmacodynamics

Indexed keywords

AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; LEVOFLOXACIN; MOXIFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; BLOOD SAMPLING; COMPUTER ANALYSIS; COMPUTER SIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INFECTION CONTROL; INOCULATION; LUNG ALVEOLUS EPITHELIUM; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; SEROTYPE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; AZITHROMYCIN; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MUTATION; OFLOXACIN; PNEUMONIA, PNEUMOCOCCAL; QUINOLINES; SERUM BACTERICIDAL TEST; STREPTOCOCCUS PNEUMONIAE;

EID: 33748028807     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl250     Document Type: Article

References (35)

1. Courvalin P. Antimicrobial drug resistance: Prediction is very difficult, especially about the future. Emerg Infect Dis 2005; 11: 1503-6.
2. Nuermberger EL, Bishai WR. Antibiotic resistance in Streptococcus pneumoniae: What does the future hold? Clin Infect Dis 2004; 38 Suppl 4: S363-71.
3. Marco F, Bouza E, Garcia-de-Lomas J et al. Streptococcus pneumoniae in community-acquired respiratory tract infections in Spain: The impact of serotype and geographical, seasonal and clinical factors on its susceptibility to the most commonly prescribed antibiotics. The Spanish Surveillance Group for Respiratory Pathogens. J Antimicrob Chemother 2000; 46: 557-64.
4. Garcia-Rey C, Aguilar L, Baquero F. Influences of different factors on prevalence of ciprofloxacin resistance in Streptococcus pneumoniae in Spain. Antimicrob Agents Chemother 2000; 44: 3481-2.
5. Perez-Trallero E, Garcia-de-la-Fuente C, Garcia-Rey C et al. Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 2005; 49: 1965-72.
6. Perez-Trallero E, Garcia-Rey C, Martin-Sanchez AM et al. Activities of six different quinolones against clinical respiratory isolates of Streptococcus pneumoniae with reduced susceptibility to ciprofloxacin in Spain. Antimicrob Agents Chemother 2002; 46: 2665-7.
7. Balcabao IP, Alou L, Aguilar L et al. Influence of the decrease in ciprofloxacin susceptibility and the presence of human serum on the in vitro susceptibility of Streptococcus pneumoniae to five new quinolones. J Antimicrob Chemother 2001; 48: 907-9.
8. MacDougall C, Guglielmo BJ, Maselli J et al. Antimicrobial drug prescribing for pneumonia in ambulatory care. Emerg Infect Dis 2005; 11: 380-4.
9. Goossens H, Ferech M, Vander Stichele R et al. Outpatient antibiotic use in Europe and association with resistance: A cross-national database study. Lancet 2005; 365: 579-87.
10. Davidson R, Cavalcanti R, Brunton JL et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346: 747-50.
11. Pérez-Trallero E, Marimón JM, González A et al. In vivo development of high-level fluoroquinolone resistance in Streptococcus pneumoniae in chronic obstructive pulmonary disease. Clin Infect Dis 2005; 41: 560-4.
12. Perez-Trallero E, Marimon JM, Iglesias L et al. Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates. Emerg Infect Dis 2003; 9: 1159-62.
13. Boswell FJ, Andrews JM, Jevons G et al. Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance. J Antimicrob Chemother 2002; 50: 495-502.
14. Sevillano D, Calvo A, Gimenez MJ et al. Bactericidal activity of amoxicillin against non-susceptible Streptococcus pneumoniae in an in vitro pharmacodynamic model simulating the concentrations obtained with the 2000/125 mg sustained-release co-amoxiclav formulation. J Antimicrob Chemother 2004; 54: 1148-51.
15. Chien SC, Rogge MC, Gisclon LG et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother 1997; 41: 2256-60.
16. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997; 32: 101-19.
17. Lee W, Hafkin B, Lee ID et al. Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects. Antimicrob Agents Chemother 1997; 41: 2196-200.
18. Lubasch A, Keller I, Borner K et al. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000; 44: 2600-3.
19. Capitano B, Mattoes HM, Shore E et al. Steady-state intrapulmonay concentrations of moxifloxacin, levofloxacin and azithromycin in older adults. Chest 2004; 125: 965-73.
20. Stass H, Bottcher MF, Ochmann K. Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400 mg dose to healthy volunteers. Clin Pharmacokinet 2001; 40 Suppl 1: 39-48.
21. Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999; 43 Suppl B: 83-90.
22. Sullivan JT, Woodruff M, Lettieri J et al. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob Agents Chemother 1999; 43: 2793-7.
23. Lode H. The pharmacokinetics of azithromycin and their clinical significance. Eur J Clin Microbiol Infect Dis 1991; 10: 807-12.
24. Florea NR, Tessier PR, Zhang C et al. Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae. Antimicrob Agents Chemother 2004; 48: 1215-21.
25. Rodvold KA, Gotfried MH, Danziger LH et al. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob Agents Chemother 1997; 41: 1399-402.
26. Andrews JM. Microbiological assays. In: Reeves DS, Wise R, Andrews JM, White LO, eds. Clinical Antimicrobial Assays. Oxford: Oxford University Press, 1999; 35-44.
27. Bonnet M, Van der Auwera P. In vitro and in vivo intraleukocytic accumulation of azithromycin (CP-62, 993) and its influence on ex vivo leukocyte chemiluminescence. Antimicrob Agents Chemother 1992; 36: 1302-9.
28. MacGowan AP, Rogers CA, Holt HA et al. Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 2003; 47: 1088-95.
29. Chen DK, McGeer A, de Azavedo JC et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999; 341: 233-9.
30. Reynolds HY. Chronic bronchitis and acute infectious exacerbations. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. New York: Churchill Livingstone, 1995; 608-19.
31. Klepser ME, Ernst EJ, Petzold CR et al. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model. Antimicrob Agents Chemother 2001; 45: 673-8.
32. Alkorta M, Gimenez MJ, Vicente D et al. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point. Int J Antimicrob Agents 2005; 25: 163-7.
33. MacGowan AP, Bowker KE. Mechanism of fluoroquinolone resistance is an important factor in determining the antimicrobial effect of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 2003; 47: 1096-100.
34. Cafini F, Alou L, Sevillano D et al. Bactericidal activity of moxifloxacin against multidrug-resistant Streptoccocus pneumoniae at clinically achievable serum and epithelial lining fluid concentrations compared with three other antimicrobials. Int J Antimicrob Agents 2004; 24: 334-8.
35. DeRyke CA, Lee SY, Kuti JL et al. Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: Impact on the development of resistance. Drugs 2006; 66: 1-14.